Press Releases
Novo Nordisk presents new semaglutide cardiovascular data across multiple chronic diseases at the American College of Cardiology 74th Annual Scientific Sessions
Data spans various cardiometabolic conditions, including type 2 diabetes (T2D), obesity, peripheral arterial disease, and chronic kidney diseaseSOUL, a phase 3 trial, explored reduction of major adverse cardiovascular events (MACE)
